Myricetin

Toxicity: Standard Handling (A)

A cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC₅₀<3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (K_i = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC₅₀ = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC₅₀<40 µM) and MMP-2 (IC₅₀<24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (K_i = ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC₅₀ of 43 µM.

Lee, K.W., et al. 2007. Carcinogenesis28, 1918.
Holder, S., et al. 2007. Mol. Cancer Ther.6, 163.
Strobel, P., et al. 2005. Biochem. J.386, 471.
Ko, C.H., et al. 2005. Mol. Cancer Ther.4, 281.
Ko, C.H., et al. 2005. Biochem. Pharmacol.69, 913.
Ko, W.C., et al. 2004. Biochem. Pharmacol.68, 2087.
Walker, E.H., et al. 2000. Mol. Cell6, 909.
Agullo, G., et al. 1997. Biochem. Pharmacol.53, 1649.
Hagiwara, M., et al. 1988. Biochem. Pharmacol.37, 2987.

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany